This report includes a dedicated chapter covering supply chain exposure, export controls, sanctions risk, and regulatory shifts affecting High Mobility Group Protein B1 Market.
Market Overview
High Mobility Group Protein B1 (HMGB1) also known as High mobility group box 1 or SBP-1 is protein encoded by HMGB1 gene. HMGB1 is secreted by immune cells such as monocytes, macrophages, and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. High Mobility Group Box protein 1 (HMGB1) is a non-alkaline (non-histonic) DNA-binding protein, it is normally localized in the nucleus as part of the chromatin. High Mobility Group Protein B1 is member of chromatin proteins which also includes, HMG1, HMG 2, HMG 14, and HMG 17.
HMGB1 with its high positive charge binds to DNA leads to oxidation, hyperacetylation and posttranslational modifications. HMGB1 is responsible for Stabilization of the nucleosomal structure and regulation of gene transcription in chromatin. It is released by necrotic cells hence act as chaperone to shuttle nuclei acids into the endosomal compartment of APCs. Nucleic acid sensors like TLR9 trigger due to High Mobility Group Protein B1 (HMGB1) . HMGB1 also has the ability to bind LPS, at the level of lipid A, possibly because of its high positive electric charge. It can chaperone to the CD14-TLR4 MD2 complex, increasing the response of macrophages to the LPS.
High Mobility Group Protein B1 (HMGB1) has its importance in:
- Cellular processes such as inflammation, cell differentiation and tumor cell migration.
- Clearance of apoptotic cells, such as in autoimmune diseases
- Splicing results in multiple transcript variants that encode the same protein.
- Antibodies that neutralize HMGB1 can be used to protects against damage and tissue injury during arthritis, lupus erythematosus, colitis, sepsis, endotoxemia, and ischemia.
- thermodynamic stability with electrostatic interactions between the acidic tail and the HMG box.
- The C-terminal acidic tail of HMGB1 helps in the maintenance of protein stability.
High Mobility Group Protein B1 Market : Key Player
- Affibody AB
- Cantex Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Evec Inc
- Ribomic Inc
High Mobility Group Protein B1 Market: End User / Application Type
- Autoimmune Disorders
- Cerebral Infarction
- Chemotherapy Effects
- Cancer Treatment
High Mobility Group Protein B1 Market : Product Type
- Dociparstat Sodium
- RBM-005
- EV-007156
Global High Mobility Group Protein B1 Market: Regional Analysis
-
North America
- U.S.A
- Canada
- Europe
- France
- Germany
- Spain
- UK
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South East Asia
- Latin America
- Brazil
- Middle East and Africa
High Mobility Group Protein B1 Market Report delivers a comprehensive analysis of the following parameters :
- Market Forecast for
- Market growth drivers
- Challenges and Opportunities
- Emerging and Current market trends
- Market player Capacity, Production, Revenue (Value)
- Supply (Production), Consumption, Export, Import analysis
- End-user/application Analysis
Biotechnology Markets Landscape
Report Coverage
| Parameter | Details |
|---|---|
| Base Year | 2026 |
| Historical Data | 2020 – 2025 |
| Forecast Period | 2026 – 2032 |
| Regional Scope | North America · Europe · Asia-Pacific · Latin America · MEA · RoW |
Frequently Asked Questions
The High Mobility Group Protein B1 Market report considers 2026 as the base year, with historical data from 2020 to 2025 and forecasts covering 2026 to 2032.
The report covers historical data from 2020 to 2025 and provides forecasts through 2032, giving a complete historical-to-forecast view of the market.
The study covers North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, and Rest of World — with country-level breakdowns within each region.
Yes. The report includes detailed profiles of 12+ key companies covering financials, strategy, product portfolio, and recent developments.
Yes. A dedicated section covers geopolitical risk factors and their impact on supply chains, pricing dynamics, and regional demand patterns through 2032.